
Gyan Chandra
Examiner (ID: 18281, Phone: (571)272-2922 , Office: P/1646 )
| Most Active Art Unit | 1646 |
| Art Unit(s) | 1646, 1674 |
| Total Applications | 1390 |
| Issued Applications | 798 |
| Pending Applications | 162 |
| Abandoned Applications | 473 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20362811
[patent_doc_number] => 20250352623
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-20
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING DIABETES
[patent_app_type] => utility
[patent_app_number] => 19/281547
[patent_app_country] => US
[patent_app_date] => 2025-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22109
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19281547
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/281547 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | Jul 24, 2025 | Pending |
Array
(
[id] => 20134971
[patent_doc_number] => 20250242015
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-31
[patent_title] => SELF-ASSEMBLING NANOPARTICLES
[patent_app_type] => utility
[patent_app_number] => 19/067426
[patent_app_country] => US
[patent_app_date] => 2025-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 94312
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19067426
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/067426 | SELF-ASSEMBLING NANOPARTICLES | Feb 27, 2025 | Pending |
Array
(
[id] => 20031861
[patent_doc_number] => 20250170083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-29
[patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY
[patent_app_type] => utility
[patent_app_number] => 19/041480
[patent_app_country] => US
[patent_app_date] => 2025-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1964
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19041480
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/041480 | Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy | Jan 29, 2025 | Issued |
Array
(
[id] => 20031861
[patent_doc_number] => 20250170083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-29
[patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY
[patent_app_type] => utility
[patent_app_number] => 19/041480
[patent_app_country] => US
[patent_app_date] => 2025-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1964
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19041480
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/041480 | Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy | Jan 29, 2025 | Issued |
Array
(
[id] => 19860763
[patent_doc_number] => 20250099549
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-27
[patent_title] => GLP-1 RECEPTOR AGONISTS IN DEMENTIA
[patent_app_type] => utility
[patent_app_number] => 18/979068
[patent_app_country] => US
[patent_app_date] => 2024-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13622
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18979068
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/979068 | GLP-1 RECEPTOR AGONISTS IN DEMENTIA | Dec 11, 2024 | Pending |
Array
(
[id] => 19860763
[patent_doc_number] => 20250099549
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-27
[patent_title] => GLP-1 RECEPTOR AGONISTS IN DEMENTIA
[patent_app_type] => utility
[patent_app_number] => 18/979068
[patent_app_country] => US
[patent_app_date] => 2024-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13622
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18979068
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/979068 | GLP-1 RECEPTOR AGONISTS IN DEMENTIA | Dec 11, 2024 | Pending |
Array
(
[id] => 20039267
[patent_doc_number] => 20250177489
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-05
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING DIABETES
[patent_app_type] => utility
[patent_app_number] => 18/967259
[patent_app_country] => US
[patent_app_date] => 2024-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21698
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18967259
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/967259 | Compositions and methods for treating diabetes | Dec 2, 2024 | Issued |
Array
(
[id] => 20014442
[patent_doc_number] => 20250152664
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-15
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/929081
[patent_app_country] => US
[patent_app_date] => 2024-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15567
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18929081
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/929081 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | Oct 27, 2024 | Pending |
Array
(
[id] => 19744024
[patent_doc_number] => 20250032589
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => Insulin Derivative
[patent_app_type] => utility
[patent_app_number] => 18/889097
[patent_app_country] => US
[patent_app_date] => 2024-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23672
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18889097
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/889097 | Insulin Derivative | Sep 17, 2024 | Abandoned |
Array
(
[id] => 19931746
[patent_doc_number] => 12304943
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-20
[patent_title] => April and BAFF inhibitory immunomodulatory proteins and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 18/807825
[patent_app_country] => US
[patent_app_date] => 2024-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 35
[patent_no_of_words] => 55563
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18807825
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/807825 | April and BAFF inhibitory immunomodulatory proteins and methods of use thereof | Aug 15, 2024 | Issued |
Array
(
[id] => 19360847
[patent_doc_number] => 20240262881
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/634496
[patent_app_country] => US
[patent_app_date] => 2024-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 102214
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18634496
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/634496 | Fusion proteins for the treatment of cardiometabolic diseases | Apr 11, 2024 | Issued |
Array
(
[id] => 19777466
[patent_doc_number] => 12226487
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-18
[patent_title] => Therapeutic derivatives of interleukin-22
[patent_app_type] => utility
[patent_app_number] => 18/628440
[patent_app_country] => US
[patent_app_date] => 2024-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 26
[patent_no_of_words] => 20042
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18628440
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/628440 | Therapeutic derivatives of interleukin-22 | Apr 4, 2024 | Issued |
Array
(
[id] => 19792188
[patent_doc_number] => 12233111
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-25
[patent_title] => Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/444463
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 55
[patent_figures_cnt] => 55
[patent_no_of_words] => 76898
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18444463
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/444463 | Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof | Feb 15, 2024 | Issued |
Array
(
[id] => 19233762
[patent_doc_number] => 20240190954
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 18/510553
[patent_app_country] => US
[patent_app_date] => 2023-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15254
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18510553
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/510553 | ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR | Nov 14, 2023 | Pending |
Array
(
[id] => 19157747
[patent_doc_number] => 20240150454
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS
[patent_app_type] => utility
[patent_app_number] => 18/499523
[patent_app_country] => US
[patent_app_date] => 2023-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56309
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18499523
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/499523 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | Oct 31, 2023 | Pending |
Array
(
[id] => 19157747
[patent_doc_number] => 20240150454
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS
[patent_app_type] => utility
[patent_app_number] => 18/499523
[patent_app_country] => US
[patent_app_date] => 2023-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56309
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18499523
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/499523 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | Oct 31, 2023 | Pending |
Array
(
[id] => 19157747
[patent_doc_number] => 20240150454
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS
[patent_app_type] => utility
[patent_app_number] => 18/499523
[patent_app_country] => US
[patent_app_date] => 2023-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56309
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18499523
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/499523 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | Oct 31, 2023 | Pending |
Array
(
[id] => 19034150
[patent_doc_number] => 20240083965
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => PRODRUGS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/384511
[patent_app_country] => US
[patent_app_date] => 2023-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20610
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 203
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18384511
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/384511 | PRODRUGS AND USES THEREOF | Oct 26, 2023 | Pending |
Array
(
[id] => 19081893
[patent_doc_number] => 20240108694
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-04
[patent_title] => METHOD OF DELIVERING A SOMATOSTATIN COMPOUND INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
[patent_app_type] => utility
[patent_app_number] => 18/481875
[patent_app_country] => US
[patent_app_date] => 2023-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23389
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481875
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/481875 | METHOD OF DELIVERING A SOMATOSTATIN COMPOUND INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | Oct 4, 2023 | Pending |
Array
(
[id] => 19081893
[patent_doc_number] => 20240108694
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-04
[patent_title] => METHOD OF DELIVERING A SOMATOSTATIN COMPOUND INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
[patent_app_type] => utility
[patent_app_number] => 18/481875
[patent_app_country] => US
[patent_app_date] => 2023-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23389
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481875
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/481875 | METHOD OF DELIVERING A SOMATOSTATIN COMPOUND INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | Oct 4, 2023 | Pending |